Patents by Inventor Martin Roecken

Martin Roecken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for Classifying a Patient's Responsiveness to Immune Checkpoint Inhibitor Therapy
    Publication number: 20220235423
    Abstract: The present invention relates to a method ex vivo for classifying a patient in need as non-responder or responder to immune checkpoint inhibitor therapy, and the use of a gene set for classifying a patient in need as non-responder or responder to immune checkpoint inhibitor therapy.
    Type: Application
    Filed: February 14, 2022
    Publication date: July 28, 2022
    Inventors: Martin Röcken, Olaf Rieß, Franz Joachim Hilke, Ellen Brenner
  • Method of inducing senescence in tumor cells by administrating TNF-a in combination with IFNa or IFNy
    Patent number: 10046029
    Abstract: The present invention relates to a combination of at least two different substances, one of which activates the STAT1-signalling cascade and the other of which activates the TNFR1/CD95-signalling cascade in order to induce permanent growth arrest—i.e. senescence—in pre-malignant or malignant tumors or tumor cells. This induction of permanent growth arrest does not depend on cytotoxicity and does not primarily attempt to kill tumor cells, although this may occur. The induction serves to treat and/or prevent tumors by permanent growth arrest. The combination is used for therapeutic or preventative senescence induction in tumors, in which the STAT1- and TNFR1/CD95-signalling cascade can be activated and in which p16lnk4a is present. The invention transfers tumor cells and, contrary to many other therapies, the tumor stem cells, into permanent growth arrest.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: August 14, 2018
    Inventor: Martin Roecken
  • USE OF ACTIVE SUBSTANCE COMBINATIONS FOR INDUCING TUMOUR SENESCENCE
    Publication number: 20150343024
    Abstract: The present invention relates to a combination of at least two different substances, one of which activates the STAT1-signalling cascade and the other of which activates the TNFR1/CD95-signalling cascade in order to induce permanent growth arrest—i.e. senescence—in pre-malignant or malignant tumors or tumor cells. This induction of permanent growth arrest does not depend on cytotoxicity and does not primarily attempt to kill tumor cells, although this may occur. The induction serves to treat and/or prevent tumors by permanent growth arrest. The combination is used for therapeutic or preventative senescence induction in tumors, in which the STAT1- and TNFR1/CD95-signalling cascade can be activated and in which p16lnk4a is present. The invention transfers tumor cells and, contrary to many other therapies, the tumor stem cells, into permanent growth arrest.
    Type: Application
    Filed: December 10, 2013
    Publication date: December 3, 2015
    Inventor: Martin RÖCKEN
  • Method and substances for treating T-cell mediated autoimmune diseases
    Patent number: 8618178
    Abstract: The invention relates to methods for treating T cell mediated autoimmune diseases, such as psoriasis and multiple sclerosis, in a human in need thereof, wherein a therapeutically effective amount of a substance which lowers the cellular glutathione content is administered to the human.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: December 31, 2013
    Assignee: Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum
    Inventors: Martin Roecken, Kamran Ghoreschi, Christina Mathilde Weigert
  • METHOD AND SUBSTANCES FOR TREATING T-CELL MEDIATED AUTOIMMUNE DISEASES
    Publication number: 20100004210
    Abstract: The invention relates to methods for treating T cell mediated autoimmune diseases, such as psoriasis and multiple sclerosis, in a human in need thereof, wherein a therapeutically effective amount of a substance which lowers the cellular glutathione content is administered to the human.
    Type: Application
    Filed: May 28, 2009
    Publication date: January 7, 2010
    Inventors: Martin Roecken, Kamran Ghoreschi, Christina Mathilde Weigert